Related references
Note: Only part of the references are listed.Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review
Antonio Toscano et al.
JOURNAL OF NEUROLOGY (2013)
Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease
Thomas Hundsberger et al.
JOURNAL OF NEUROLOGY (2013)
Low-frequency enzyme replacement therapy in late-onset pompe disease
Dar-Shong Lin et al.
MUSCLE & NERVE (2013)
The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?
Robin Lachmann et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Autophagy and mitochondria in Pompe disease: Nothing is so new as what has long been forgotten
Nina Raben et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2012)
The genotype-phenotype correlation in Pompe disease
Marian Kroos et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2012)
Orphan Drugs for Rare Diseases Is it Time to Revisit Their Special Market Access Status?
Steven Simoens et al.
DRUGS (2012)
36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy
Caroline Regnery et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2012)
Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years
C. Angelini et al.
JOURNAL OF NEUROLOGY (2012)
Effect of rapid cessation of enzyme replacement therapy: A report of 5 cases and a review of the literature
Agnieszka Jurecka et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study
Juna M. de Vries et al.
ORPHANET JOURNAL OF RARE DISEASES (2012)
Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study
Nadine A. M. E. van der Beek et al.
ORPHANET JOURNAL OF RARE DISEASES (2012)
MAKING DIAGNOSIS OF POMPE DISEASE AT A PRESYMPTOMATIC STAGE: TO TREAT OR NOT TO TREAT?
K. Laloui et al.
NEUROLOGY (2011)
Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II
Bruno Bembi et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial
S. Strothotte et al.
JOURNAL OF NEUROLOGY (2010)
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease.
Ans T. van der Ploeg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease
N. A. M. E. Van der Beek et al.
NEUROMUSCULAR DISORDERS (2009)
Lysosomal storage disease 2 - Pompe's disease
Ans T. van der Ploeg et al.
LANCET (2008)
Management and treatment of glycogenosis type II
B. Bembi et al.
NEUROLOGY (2008)
Therapeutic approaches in glycogen storage disease type II/Pompe disease
Benedikt Schoser et al.
NEUROTHERAPEUTICS (2008)
Recombinant human acid α-glucosidase -: Major clinical benefits in infantile-onset Pompe disease
P. S. Kishnani et al.
NEUROLOGY (2007)
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease
Beth L. Thurberg et al.
LABORATORY INVESTIGATION (2006)
Reference values for the 6-min walk test in healthy subjects 20-50 years old
Alfredo Chetta et al.
RESPIRATORY MEDICINE (2006)
Long term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk
JMP Van den Hout et al.
PEDIATRICS (2004)
Share Paper
